Loading search results

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Diagnosis of multiple myeloma meeting at least 1 of the following criteria: * Relapsed disease after a response to standard first-line chemotherapy (e.g., vincristine, doxorubicin, and dexamethasone \[VAD\] OR melphalan and prednisone) or first-line high-dose chemotherapy * Refractory disease (failed to achieve at least stable disease) to most recent chemotherapy with or without systemic corticosteroids * Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of ≥ 1 g/dL AND/OR urine monoclonal immunoglobulin spike of ≥ 200 mg/24 hours * No non-secretory myeloma * No plasma cell leukemia PATIENT CHARACTERISTICS: Age * 18 and over Performance status * Karnofsky 60-100% Life expectancy * More than 3 months Hematopoietic * Platelet count ≥ 50,000/mm\^3 (30,000/mm\^3 if bone marrow is extensively infiltrated) * Hemoglobin ≥ 8.0 g/dL * Absolute neutrophil count ≥ 1,000/mm\^3 * Pancytopenia secondary to multiple myeloma or hypersplenism allowed Hepatic * AST and ALT ≤ 3 times upper limit of normal (ULN) * Bilirubin ≤ 2 times ULN (unless clearly related to disease) * No known active hepatitis B or C infection Renal * Calcium \< 14 mg/dL Cardiovascular * No evidence of acute ischemia or new conduction system abnormality by electrocardiogram * No myocardial infarction within the past 6 months * No New York Heart Association class III or IV heart failure * No poorly controlled hypertension * No prolonged corrected QT interval (\> 460 ms) with potassium \> 4 mmol/L and magnesium ≥ 1.8 mmol/L Other * No active infection * No POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) * No diabetes mellitus * No other serious medical or psychiatric illness that would preclude study participation * No known allergic reaction attributable to compounds of similar chemical or biological composition to study drugs * No history of grand mal seizures * HIV negative * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy * More than 4 weeks since prior immunotherapy or antibody therapy Chemotherapy * See Disease Characteristics * More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas) Endocrine therapy * See Disease Characteristics * No other concurrent corticosteroids Radiotherapy * More than 4 weeks since prior radiotherapy Surgery * More than 4 weeks since prior major surgery Other * No other concurrent investigational agents

Study Sites (19)

Palo Verde Hematology Oncology

Glendale, Arizona, 85304, United States

Comprehensive Blood and Cancer Center

Bakersfield, California, 93309-0633, United States

Southbay Oncology / Hematology Medical Group

Campbell, California, 95008, United States

Fountain Valley, California, 92708, United States

Hematology-Oncology Medical Group of Fresno, Incorporated

Fresno, California, 93720, United States

Hematology Oncology Medical Group of Orange County, Incorporated

Orange, California, 92868, United States

Cancer Care Associates Medical Group - Redondo Beach

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier

NCT00085345

Data provider

ClinicalTrials.gov

Source updated

2013-07-10

Normalization version

ctgov-legacy-1

Source retrieved: 2026-10-25 22:35:48 UTC

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Conditions

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (19)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Intervention Hierarchy (Ancestors)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Conditions

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (19)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations

Intervention Hierarchy (Ancestors)